The HHS wants to move oversight of the controversial drug discount program to the CMS, which has a more aggressive history ...

A federal judge ruled that the government did not violate the law in a dispute with J&J over the 340B drug discount program.

Hospitals could be on the hook for significantly higher outpatient drug prices. Because of the cuts to Medicaid, hospitals in the 340B program will see fewer Medicaid patients and may risk losing ...

President Trump is attempting to reshape America’s biotech industry with two primary objectives. He wants more medicines to ...

Two of the world’s largest pharmaceutical companies are suing Oklahoma to stop a new state law dealing with a $70 billion ...

A federal lawsuit is targeting a new Oklahoma law that puts conditions on how much drug manufacturers can charge when selling ...

Employers are advocating for changes to the 340B Drug Pricing Program, arguing that it allows hospitals to "buy low and sell high" by purchasing discounted medications and charging insured ...

A U.S. District Court for the District of Columbia judge June 27 ruled against Johnson & Johnson and sided with the ...

Johnson & Johnson failed to convince a federal judge that the US government acted unlawfully when it rejected the company’s ...

President Donald Trump’s One Big Beautiful Bill, signed into law last week, reintroduces broader exemptions for orphan drugs from the IRA’s drug price negotiation program—a move welcomed by the ...

The U.S. District Court for the Middle District of Tennessee June 30 denied a motion for a preliminary injunction by AbbVie ...